Monoclonal antibody · Kills target cells, directed at Interleukin-3 receptor subunit alpha (IL3RA) · developed by Molecular Partners
MP0533 is an agent administered by intravenous infusion that is studied in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05673057 | Phase 1 | Leukemia | Completed | MOLN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AcuteLeukemiaMyeloidNewly Diagnosed
Updated Oct 25, 2026. Something wrong or missing? Report it on the MOLN page.
See MOLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MOLN catalysts and pipeline →